Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].

Schmieder RE, Krekler M.

MMW Fortschr Med. 2005 Oct 6;147 Suppl 3:97-101. German.

PMID:
16261944
4.

[Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].

Tschöpe C, Tschöpe R, Unger T.

MMW Fortschr Med. 2006 Jun 22;148(25):48. German. No abstract available.

PMID:
16859162
5.

[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].

Schmieder RE, Krekler M.

MMW Fortschr Med. 2005 Aug 4;147(31-32):43. German. No abstract available.

PMID:
16128197
6.

The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.

Rosenstock J, Rossi L, Lin CS, MacNeil D, Osbakken M.

J Clin Pharm Ther. 1998 Dec;23(6):433-40.

PMID:
10048504
7.
8.

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH.

Kidney Int. 2005 Sep;68(3):1190-8.

9.

Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.

Huang QF, Sheng CS, Li Y, Ma GS, Dai QY, Wang JG; INCENT Investigators.

Drugs R D. 2013 Jun;13(2):109-17. doi: 10.1007/s40268-013-0013-9.

10.

Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.

Ketelhut R, Bramlage P.

Clin Drug Investig. 2010;30(5):301-11. doi: 10.2165/11533370-000000000-00000.

PMID:
20384386
11.

Irbesartan and hydrochlorothiazide association in the treatment of hypertension.

Derosa G, Ferrari I, Cicero AF.

Curr Vasc Pharmacol. 2009 Apr;7(2):120-36. Review.

PMID:
19355995
12.

Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.

Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S.

Clin Exp Hypertens. 2009 Oct;31(7):572-84. doi: 10.3109/10641960902929420.

PMID:
19886855
13.

Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.

Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA; INCLUSIVE Investigators.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):470-80.

14.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
15.
16.

[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].

Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish.

PMID:
11601118
17.

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

N Engl J Med. 2001 Sep 20;345(12):870-8.

19.

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.

Bramlage P.

Vasc Health Risk Manag. 2009;5(1):213-24. Epub 2009 Apr 8. Review.

20.

The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.

Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, Weber MA; INCLUSIVE Investigators.

J Clin Hypertens (Greenwich). 2005 Oct;7(10):578-86.

Supplemental Content

Support Center